Development
Alnylam Pharmaceuticals, Inc.
ALNY
$300.83
-$7.17-2.33%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -193.31% | 153.53% | -58.54% | 16.09% | 48.88% |
| Total Depreciation and Amortization | 1.87% | 0.36% | -10.09% | 4.80% | 20.51% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -52.45% | 26.03% | 90.61% | 5.25% | -75.76% |
| Change in Net Operating Assets | -73.39% | -60.47% | 174.97% | -529.89% | -393.83% |
| Cash from Operations | -108.29% | 709.32% | 64.57% | -26.14% | -14.48% |
| Capital Expenditure | 10.43% | -7.37% | -14.60% | 35.79% | -31.04% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -3,661.11% | -12.18% | 111.56% | 47.30% | -135.80% |
| Cash from Investing | -2,135.75% | -23.54% | 88.57% | 45.52% | -144.57% |
| Total Debt Issued | -- | -- | -- | -- | -100.08% |
| Total Debt Repaid | -- | -- | -- | -- | 100.00% |
| Issuance of Common Stock | 24.55% | -49.78% | 16.58% | -25.29% | -62.94% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.01% | 108.33% | 0.00% | -46.67% | -4.25% |
| Cash from Financing | 18.38% | -37.94% | 15.15% | -26.90% | -78.64% |
| Foreign Exchange rate Adjustments | 266.32% | -4,940.00% | -105.97% | 34.40% | -20.01% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -158.72% | 2,699.47% | 92.56% | 6.13% | -141.56% |